MediCrops became one of the first Swiss companies to receive an operating license to cultivate cannabis for medical purposes from Swissmedic. This is a milestone for the company, as the license will allow the import and export of seeds, plant growth, and the characterization of genetics, all prerequisites for the success of their biopôle-based R&D activity aiming at developing THC-based medicines.